• Tuesday, May 10, 2022 @ 12:00 am

Cosmo should see a sharp increase in revenues boosted by the recovery of its endoscopy business, which was severely impacted by the COVID-19 pandemic, and the US launch of Winlevi in acne. Revenues from game changer GI Genius could be transformational. Cosmo has returned to sustainable profits.

Key catalysts include:

1. Start phase III trial Aemcolo in IBS-D (2022)

2. Start confirmatory Lumeblue phase III trial for US approval (2022)

3. Start phase III trial Breezula in male alopecia (H2 2022)

Cosmo Valuation Report "Back to the roots"

You may also be interested in